Late-onset Alzheimer's disease is a debilitating, progressive neurodegenerative disease that affects about 7 million ...

A new Alzheimer’s treatment at Hancock Regional Hospital has both doctors and patients feeling cautiously optimistic.

Jan. 15, 2025 — Scientists have come up with a drug that is a potential candidate for tackling memory deficits in the early stages of the disease in rodents. ... New Innovative Local Treatment ...

There are two kinds of risk factors for dementia: non-modifiable and modifiable. Non-modifiable risk factors are ones that cannot be changed or eliminated, like aging, family history and genetics.

PMN310, a humanized IgG1 antibody, is engineered to selectively target toxic oligomers of amyloid-beta (AβO)—which are believed to be a key driver of Alzheimer’s pathology—while avoiding interaction ...

In the study, Asians had a longer life expectancy than Europeans and Americans, while people with Alzheimer’s disease were more likely to survive longer than those with other forms of dementia ...

NEW YORK, Jan. 8, 2025 /PRNewswire/ -- Declining blood levels of two molecules that occur naturally in the body track closely with worsening Alzheimer’s disease, particularly in women. Levels were ...

It can help identify people at risk of Alzheimer's disease and screen for conditions like Parkinson's disease, brain tumors, substance abuse, and head trauma. Introduced in 2005, the MoCA test is an ...

Monoclonal antibody anti-amyloid immunotherapies (AATs) have been approved for clinical use for patients with mild cognitive impairment or early dementia due to Alzheimer's disease in multiple ...

With 28 patent filings and a commitment to innovation, IGC Pharma is dedicated to advancing pharmaceutical treatments and improving the lives of those affected by Alzheimer's and related conditions.

As dementia progresses, there may come a time when the person will struggle to manage their finances and affairs. At some point, they may need extra support, or for someone to manage their money for ...

1 AD is a neurodegenerative disorder marked by progressive memory loss and other cognitive decline that disrupts daily life, leaving patients requiring around-the-clock care and ultimately, leading to ...